Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: Results of a randomized, multicenter, controlled trial

AIDS

Volumn 12, Issue 1, 1998, Pages 65-74

  Kuritzkes, Daniel R ^a   Parenti, David ^b   Ward, Douglas J ^c   Rachlis, Anita ^d   Wong, Roberta J ^e   Mallon, Kenneth P ^e   Rich, William J ^e   Jacobson, Mark A ^f  

^a UNIVERSITY OF COLORADO   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c Dupont Circle Physicians Group   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e AMGEN INC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Bacterial infection; Hematology; Hematopoietic growth factors; Hospitalization; Neutropenia; Outpatient; Randomized study

Indexed keywords

CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VIRUS RNA;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANEMIA; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MORBIDITY; MULTICENTER STUDY; MYALGIA; MYCOSIS; NAUSEA; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CD4 LYMPHOCYTE COUNT; FEMALE; FILGRASTIM; HIV; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; OUTPATIENTS; PLATELET COUNT; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0031982659     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199801000-00008     Document Type: Article

References (33)

1. Aboulafia DM, Mitsuyasu RT: Hematologic abnormalities in AIDS. Hematol Oncol Clin North Am 1991, 5:195-214.
2. Fischi M, Parker CB, Pettinelli C, et al.: A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990, 323:1009-1014.
3. Sawka CA, Shepherd FA, Brandwein J, Burkes RL, Sutton DM, Warner E: Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve week chemotherapy program. Leuk Lymphoma 1992, 8:213-220.
4. Castelia A, Croxson TS, Mildvan D, Win DH, Zalusky R: The bone marrow in AIDS. A histologic, hematologic, and microbiologic study. Am J Clin Pathol 1985, 84:425-432.
5. Moses AV, Williams S, Heneveld ML, et al.: Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood 1996, 87:919-925.
6. Nichols L, Florentine B, Lewis W, Sattler F, Rarick MU, Brynes RK: Bone marrow examination for the diagnosis of mycobacterial and fungal infections in the acquired immunodeficiency syndrome. Arch Pathol Lab Med 1991, 115:1125-1132.
7. Zauli G, Vitale M, Re MC, et al.: In vitro exposure to human immunodeficiency virus type 1 induces apoptotic cell death of factor-dependent TF-1 hcmatopoietic cell line. Blood 1994, 83:167-175.
8. Rule SA, Hooker M, Costello C, Luck W, Hoffbrand AV: Serum vitamin B12 and transcobalamin levels in early HIV disease. Am J Hematol 1994, 47:167-171.
9. Donahue RE, Johnson MM, Zon LI, Clark SC, Groopman JE: Suppression of in vitro haematopoiesis following human immunodeficiency virus infection. Nature 1987, 326:200-203.
10. Shaunak S, Bartiett JA: Zidovudine-induced neutropenia: are we too cautious? Lancet 1989, ii:91-92.
11. Moore RD, Keruly JC, Chaisson RE: Neutropenia and bacterial infection in acquired immunodeficiency syndrome. Arch Intern Med 1995, 155:1965-1970.
12. Caperna J, Barber E, Mathews WC: Estimating neutropenic risk of bacteremia among HIV-infected patients by secondary analysis of clinical and laboratory data: a retrospective cohort. American Federation of Clinical Research Regional Meeting. Carmel, California, February 1996 [abstract 125].
13. Eng RHK, Yen K, Tecson-Tumang F, Smith SM, Akgun K: Risk of gram-negative bacteremia during neutropenia in patients with AIDS. Infect Dis Clin Pract 1994, 3:373-375.
14. Keiser P, Higgs E, Smith J: Neutropenia is associated with bacteremia in patients Infected with the human immunodeficiency virus. Am ; Med Sci 1996, 312:118-122.
15. Jacobson MA, Liu RC-C, Davies D, Cohen PT: HIV disease-related neutropenia and the risk of hospitalization for serious bacterial Infection. Arch Intern Med 1997, 157:1825-1831
16. Carpenter CC, Fischi MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society USA. JAMA 1996, 276:146-154.
17. Pluda JM, Mitsuyasu H, Yarchoan R: Hematologic effects of AIDS therapies. Hematol Oncol Clin North Am 1991, 5:229-248.
18. Bozzette SA, Finkelstein DM, Spector SA, et al.: A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995, 332:693-699.
19. Hochster H, Dieterich D, Bozzette S, et al.: Toxicity of combined ganciclovir and zidovudine for cytomegalovirus diseases associated with AIDS. An AIDS Clinical Trials Group Study. Ann Intern Med 1990, 113:111-117.
20. Dührsen U, Villeval JL, Boycl J, Kannourakis G, Morstyn G, Metcalf D: Effects of recombinant human granulocyte colonystimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988, 72:2074-2081.
21. Souza LM, Boone TC, Gabrilove J, et al.: Recombinanl human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986, 232:61-65.
22. Morstyn G, Campbell L, Souza LM, et al.: Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988, i:667-672.
23. Roilides E, Walsh TJ, Pizzo PA, Rubin M: Granulocyte colonystimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 1991, 163:579-583.
24. Garavelli PL, Berti P: Efficacy of recombinant granulocyte colony-stimulating factor in the long-term treatment of AIDS-related neutropenia [letter]. AIDS 1993, 7:589-590.
25. Hengge UR, Brockmeyer NH, Goos M: Granulocyte colony-stimulating factor treatment in AIDS patients. Clin Invest 1992, 70:922-926.
26. Kimura S, Matsuda J, Ikematsu S, et al.: Efficacy of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with AIDS. AIDS 1990, 4:1251-1255.
27. Mueller BU, Jacobsen F, Buller KM, Husson RN, Lewis LL, Pizzo PA: Combination treatment with azidothymidine and granulocytc colony-stimulating factor in children with human immunodeficiency virus infection. J Pediatr 1992, 121:797-802.
28. Jacobson MA, Stanley HD, Heard SE: Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients [letter]. AIDS 1992, 6:515-517.
29. Miles SA, Mitsuyasu RT, Moreno J, et al.: Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood 1991, 77:2109-2117.
30. Fleming T, Harrington D: Counting Processes and Survival Analysis. New York: John Wiley; 1991:105.
31. Hermans P, Rosenbaum W, Jou A, et al.: Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. AIDS 1996, 10:1627-1633.
32. Pitrak DL, Bak PM, De Marais P, Novak RM, Andersen BR: Depressed neutrophil Superoxide production in human immunodeficiency virus infection. J Infect Dis 1993, 167:1406-1410.
33. Hardy DW, Feinber J, Finkelstein D, et al.: A controlled trial of trimethoprim-sulfmethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992, 327:1842-1848.